- Home
- BAM vs SNY Comparison
BAM vs SNY Comparison
Compare BAM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAM
- SNY
- Stock Information
- Founded
- BAM 2022
- SNY 1994
- Country
- BAM United States
- SNY France
- Employees
- BAM N/A
- SNY N/A
- Industry
- BAM
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- BAM
- SNY Health Care
- Exchange
- BAM Nasdaq
- SNY Nasdaq
- Market Cap
- BAM 99.1B
- SNY 116.1B
- IPO Year
- BAM N/A
- SNY N/A
- Fundamental
- Price
- BAM $57.83
- SNY $49.11
- Analyst Decision
- BAM Buy
- SNY Buy
- Analyst Count
- BAM 12
- SNY 4
- Target Price
- BAM $63.35
- SNY $61.50
- AVG Volume (30 Days)
- BAM 1.9M
- SNY 3.9M
- Earning Date
- BAM 11-03-2025
- SNY 10-24-2025
- Dividend Yield
- BAM 2.92%
- SNY 3.25%
- EPS Growth
- BAM 36.33
- SNY 118.56
- EPS
- BAM 1.51
- SNY 8.65
- Revenue
- BAM $4,351,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- BAM $34.72
- SNY $1.53
- Revenue Next Year
- BAM $13.88
- SNY $7.06
- P/E Ratio
- BAM $38.30
- SNY $5.69
- Revenue Growth
- BAM 13.81
- SNY 15.65
- 52 Week Low
- BAM $41.78
- SNY $44.62
- 52 Week High
- BAM $64.10
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- BAM 47.22
- SNY 54.77
- Support Level
- BAM $56.59
- SNY $44.62
- Resistance Level
- BAM $58.99
- SNY $51.05
- Average True Range (ATR)
- BAM 1.53
- SNY 0.83
- MACD
- BAM -0.06
- SNY 0.43
- Stochastic Oscillator
- BAM 31.15
- SNY 68.73
About BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.